New Potomac Partners’s Charles River Laboratories CRL Stock Holding History

New Potomac Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$59.1K	Buy	+300	New	+$62.3K	0.03%	115
2022 Q1	–	Sell	-550	Closed	-$207K	–	62
2021 Q4	$207K	Sell	550 -150	-21%	-$58.3K	0.13%	60
2021 Q3	$289K	Sell	700 -50	-7%	-$20.8K	0.2%	59
2021 Q2	$277K	Hold	750	–	–	0.19%	58
2021 Q1	$217K	Buy	+750	New	+$208K	0.16%	60
2020 Q4	–	Sell	-750	Closed	-$170K	–	75
2020 Q3	$170K	Hold	750	–	–	0.14%	64
2020 Q2	$131K	Hold	750	–	–	0.12%	71
2020 Q1	$95K	Hold	750	–	–	0.1%	72
2019 Q4	$115K	Hold	750	–	–	0.11%	77
2019 Q3	$99K	Hold	750	–	–	0.1%	78
2019 Q2	$106K	Hold	750	–	–	0.11%	76
2019 Q1	$109K	Hold	750	–	–	0.11%	79
2018 Q4	$85K	Hold	750	–	–	0.09%	84
2018 Q3	$101K	Hold	750	–	–	0.09%	79
2018 Q2	$84K	Hold	750	–	–	0.08%	84
2018 Q1	$80K	Hold	750	–	–	0.08%	89
2017 Q4	$82K	Buy	+750	New	+$81.6K	0.08%	84

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

New Potomac Partners's CRL Position: Q3 2024 in Review

New Potomac Partners opened a new position in Charles River Laboratories (CRL) in Q3 2024: 300 shares worth $59.1K. The stake represents 0.03% of the portfolio and ranks #115 among its holdings. This is a return to the name: New Potomac Partners previously reported a position in CRL as recently as Q4 2021.

New Potomac Partners first reported a position in CRL in Q4 2017 and has held it in 17 quarters since. The position peaked at $289K in Q3 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

New Potomac Partners held 300 shares of Charles River Laboratories worth $59.1K as of Q3 2024.
Charles River Laboratories was a new New Potomac Partners position in Q3 2024.
Charles River Laboratories made up 0.03% of New Potomac Partners's portfolio in Q3 2024, its #115 holding.
New Potomac Partners first reported a position in Charles River Laboratories in Q4 2017 and has held it in 17 quarters since.
New Potomac Partners's Charles River Laboratories position peaked at $289K in Q3 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on New Potomac Partners's 13F filing for Q3 2024, filed 8 Nov 2024.